LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
LENZ Therapeutics reported Q3 2026 VIZZ net product sales of $2.6 million on over 38,000 paid prescriptions, up roughly 50% and 51% sequentially, with momentum continuing into Q4. The company announced a strategic reorganization prioritizing consumer marketing that is expected to cut projected 2027 annualized operating expenses by more than 50%, targeting $70-$75 million, with roughly $5 million in one-time charges in Q4 2026. CEO Eef Schimmelpennink will transition from the role effective December 1, 2026, with CFO Dan Chevallard appointed Interim President and CEO; Schimmelpennink will stay on as a strategic advisor into 2027.
Key figures
- Revenue
- $2.6 million
- Guidance
- 2027 operating expenses targeted at approximately $70 million to $75 million, excluding stock-based compensation (a reduction of more than 50% in projected annualized 2027 opex)
- Sga q3
- $35.8 million
- Net loss 9m
- $104.4 million
- Net loss q3
- $31.0 million
- Unique prescribers
- over 15,000
- Paid prescriptions q3
- over 38,000
- Prescription growth qoq
- 51%
- Product sales growth qoq
- 50%
- Cash and marketable securities
- $197.3 million
- One time restructuring charges
- approximately $5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.